Pacira Drug Promotion Suit Settled With Broad Concessions From FDA
This article was originally published in The Gray Sheet
Executive Summary
The agency will formally rescind Exparel warning letter and expand labeling to clarify that pain drug is not limited to any specific surgery. The drug case has been closely watched for implications on FDA's oversight of off-label communications for both drugs and devices.
You may also be interested in...
FDA Seeks To Resolve First Amendment Suit By Pacira
Judge extends date for agency response to firm's complaint as parties continue settlement talks; case reveals two chinks in FDA’s off-label regulatory regime armor, former FDA advisor says.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.